During the forecast period 2023 to 2033, the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market is expected to grow at a value of 11% CAGR, according to Future Market Insights. By the year 2033, the global market for ESR1 mutated metastatic breast cancer diagnostics is expected to rise up to a market valuation of US$ 185 Million. One of the key drivers of growth in the ESR1 mutated...

During the forecast period 2023 to 2033, the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market is expected to grow at a value of 11% CAGR, according to Future Market Insights. By the year 2033, the global market for ESR1 mutated metastatic breast cancer diagnostics is expected to rise up to a market valuation of US$ 185 Million. One of the key drivers of growth in the ESR1 mutated...

Fulvestrant is a cancer medicine sold under the brand name Fulvant. It is used for the treatment of patients with breast cancer. This medication is expected to manage tumors that are HR-positive. It is available in the fixed-dose strength of 250mg/5ml. The side effects of fulvestrant injections may include cloudy urine, difficulty in breathing, fever, and nausea. Magicine Pharma sells...

Fulvestrant is a prescription medication for breast cancer patients. It is used to treat women diagnosed with breast cancer that is estrogen-dependent. This medication is available as injectable syringes of strength 250mg/5ml. The side effects of the fulvestrant injection include irregular heartbeat, chest pain, tarry stools, and difficulty in breathing. Paznib is a formulation of...

Imarech is a cancer medicine with the generic name imatinib mesylate. The imatinib mesylate tablet is available in 400mg strength. This medicine is a cytotoxic agent. This medicine is utilized in the treatment of certain types of blood cancer called CML (chronic myeloid leukemia) and ALL (Acute lymphocytic leukemia). It is also used for treating gastrointestinal stromal tumors. The imarech...